Interview with Andrew de Guttaduaro, President, Oncolytics Biotech U.S $ONCY

Interview with Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.